Phase I, IIa, Single-Arm, Study of BCMA-CD19-IL-15/IL15sushi cCAR T for the Treatment of Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis
Latest Information Update: 16 Jan 2026
At a glance
- Drugs BCMA CD19 cCAR T-cell therapy-iCell Gene Therapeutics (Primary) ; Cyclophosphamide
- Indications Lupus nephritis; Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors iCell Gene Therapeutics
Most Recent Events
- 16 Jan 2026 New trial record